StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

NovoCure price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

NovoCure's price to sales ratio was 2.0× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 1.9× to 17.6×, with a median of 3.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.0×−0.3
2025Dec 31, 20252.3×−3.3
2024Dec 31, 20245.6×+2.4
2023Dec 29, 20233.2×−11.0
2022Dec 30, 202214.2×−0.1
2021Dec 31, 202114.3×−24.9
2020Dec 31, 202039.1×+13.2
2019Dec 31, 201925.9×+12.5
2018Dec 31, 201813.4×+1.7
2017Dec 29, 201711.8×+1.4
2016Dec 30, 201610.4×−1.0
2015Dec 31, 201511.3×–

More NovoCure figures

See a number that looks wrong?